Ponezumab is a humanized monoclonal antibody designed for the treatment of Alzheimer's disease.[1][2]
Ponezumab was developed by Pfizer Inc. In November 2011 Pfizer halted the development of ponezumab after finishing a phase 2 trial.[3]
References
- Statement On A Nonproprietary Name Adopted By The USAN Council: Ponezumab American Medical Association^
- Frontiers in Clinical Drug Research: Alzheimer Disorders Bentham Science Publishers, 2014^
- Pfizer Halts Development of Aβ Antibody alzforum.org, 2 November 2011, retrieved 2025-04-22^